41 results about "Lipid peroxide" patented technology

The invention belongs to the technical field of medicinal chemistry, and discloses a preparation method and application of a 5-aryl substituted 1, 2, 4-triazole iron death inhibitor derivative. The derivative has a structural general formula as shown in the following formula (I), wherein Ar1 and Ar2 substituent groups can be combined at will. The compound can be used for efficiently removing cell lipid peroxides and effectively inhibiting ferroptosis processes of various cells. Particularly, the compound SN26 has optimal ferroptosis inhibitory activity (786-O cell line, EC50 = 62nM), and can effectively improve acute liver injury of mice caused by concanavalin by inhibiting ferroptosis. The research is expected to be used for developing ferroptosis inhibitors and research and development of small molecule drugs for related diseases. # imgabs0 #

The invention belongs to the technical field of medicines, and particularly relates to a preparation method of a scrophularia ningpoensis extract for relieving chemotherapy-induced acute kidney injury and application of the scrophularia ningpoensis extract in preparation of a product for relieving chemotherapy-induced acute kidney injury. The preparation method comprises the following steps: putting fresh ginseng into a high-temperature and high-pressure sterilization pot, steaming at 110-120 DEG C for 1-3 hours, taking out, cooling to room temperature, and repeating the steaming cooling process for 2-5 times; and crushing the treated ginseng materials, adding a mixed strain of saccharomyces cerevisiae and lactobacillus plantarum in a mass ratio of 1: 1, fermenting for 24-72 hours, filtering fermentation liquor, and drying filter residues to obtain the black ginseng extract. The cisplatin-induced acute kidney injury is prevented and / or treated by improving oxidative stress and mitochondrial functional activity, reducing the content of lipid peroxide, inhibiting expression of inflammatory factors TNF alpha, IL1beta and COX2 and remarkably reducing the cell apoptosis rate and the level of inflammatory factors related to endoplasmic reticulum stress.

The invention provides application of a small molecule drug for promoting triple negative breast cancer ferroptosis, and belongs to the technical field of tumor treatment. The inducer can effectively kill triple negative breast cancer cells by triggering a ferroptosis pathway. The invention discovers that the inhibitor can reduce the expression of a key protein RPTOR by inhibiting the activity of an mTORCl compound, thereby weakening the anti-oxidation defense capability of triple negative breast cancer cells, greatly enhancing the accumulation of lipid peroxide, and further strongly inducing the occurrence of ferroptosis. The component of the culture medium is a DMEM (Dulbecco Modified Eagle Medium) containing 10% of fetal calf serum, and 2 [mu] M of Torinl is added at the same time. The invention discloses a new target spot of ferroptosis of the triple-negative breast cancer, and provides a new thought for treatment of the triple-negative breast cancer.

The invention belongs to the technical field of biological medicine and skin repair, and particularly relates to a recombinant extracellular matrix protein composition and application thereof in preparation of products for resisting skin photoaging. The recombinant extracellular matrix protein composition is obtained by mixing recombinant humanized III collagen, recombinant humanized chemical fibronectin and recombinant humanized elastin. Tests show that the recombinant extracellular matrix protein composition can improve the survival rate of cells damaged by UVB, reduce the generation of ROS, improve the activity of SOD, CAT and GSH-Px and the level of GSH, and reduce the content of lipid peroxide MDA. The recombinant extracellular matrix protein composition has an effective anti-oxidative damage effect and can resist skin cell damage caused by UVB.

The invention relates to the field of biological medicine, in particular to a nanoparticle for treating myocardial ischemia reperfusion injury, a preparation method and application. According to the scheme, the nanoparticles comprise liposome containing ML351, a phase change material PFP is sealed in the liposome, and a TA-Ce metal polyphenol network coating is wrapped outside the liposome. The TA-Ce coating ensures that the system actively anchors myocardial cells through multiple acting forces, continuously removes ROS, and creates a primary protection environment for the myocardial cells. Under ultrasonic triggering, the PFP in the inner core is subjected to phase change blasting, local enrichment and accurate release of ML351 are realized, lipid peroxide is reduced, a ferroptosis pathway is blocked, and sequential treatment under space-time control is realized. A network structure of TA-Ce removes ROS, and TA-Ce and ML351 inhibit lipid peroxidation, and upstream and downstream synergy is formed on an anti-oxidation and anti-ferroptosis pathway, so that the overall treatment effect is greatly enhanced.

The application relates to a composition for treating reflux esophagitis and application thereof. The composition comprises the following components in parts by weight: 2-8 parts of scutellaria baicalensis, 3-7 parts of licorice, 5-10 parts of beeswax and 80-120 parts of vegetable oil. The composition for treating reflux esophagitis contains scutellaria baicalensis, licorice, beeswax and vegetable oil, and through mutual cooperation among the components, the drug prepared from the composition can significantly increase the plasma motilin level of a patient, further increase the pressure of the lower esophageal sphincter, promote gastric emptying and prevent acid reflux, promote the recovery of reflux esophagitis, the esophagus of the patient is obviously improved, and no adverse reaction is found; meanwhile, the content of lipid peroxide can be obviously reduced, the activities of superoxide dismutase and glutathione peroxidase are increased, the esophageal mucosa is protected and treated, the pathological changes of the esophagus are obviously improved, and the treatment effect is excellent.

The invention relates to a marine-derived bifunctional enzyme as well as a coding gene and application thereof, and belongs to the technical field of biological enzymes. The amino acid sequence of the bifunctional enzyme PpLipO is as shown in SEQ ID NO. 2, and the nucleotide sequence of the bifunctional enzyme PpLipO is as shown in SEQ ID NO. 1. The enzyme comprises an alpha / beta hydrolase structural domain and an osmotic pressure induced protein structural domain, which are respectively PpLipOLip and PpLipOsmC. The novel marine-sourced bifunctional enzyme PpLipO is found for the first time, lipid peroxides are efficiently removed through the synergistic effect of two structural domains, on one hand, the problems that due to the fact that unsaturated fatty acid in fat-containing food is prone to oxidation, the nutritional value of the food is reduced, the sensory quality is degraded, and the edible safety risk is caused can be solved, and on the other hand, the marine-sourced bifunctional enzyme PpLipO can be used for efficiently removing the lipid peroxides; on the other hand, toxic lipid peroxides generated in skin oxidative injury can be cleared away, skin injury is relieved, and the compound can be used for preparing antioxidants.

The invention discloses an endoplasmic reticulum targeted ferroptosis micromolecule inducer as well as a preparation method and application thereof. The structural formula of the inducer is shown in the specification. A COX2 inhibitor (indometacin) and an endoplasmic reticulum target head (2-(4-methyl phenyl sulfonamide) acetic acid) are connected through a disulfide bond, and targeted delivery to an endoplasmic reticulum is achieved. The compound can synergistically induce endoplasmic reticulum stress, so that the content of calcium ions in tumor cells is increased, and the levels of lipid peroxide and active oxygen are increased, thereby causing a severe ferroptosis phenomenon and improving the treatment effect on cancers.

The invention relates to A61K35, in particular to hair growth essence and application of the hair growth essence in scalp aging protection. The hair growth essence is prepared from the following raw materials in parts by weight: 20 to 45 parts of active ingredients, 5.2 to 7.5 parts of glycerol, 0.015 to 0.025 part of auxiliary active ingredients, 0.6 to 0.9 part of stabilizer and 50 to 74 parts of deionized water. The hair-growing essence provided by the invention has excellent free radical scavenging activity and lipid peroxide inhibition activity, and is beneficial to prevention of alopecia caused by oxidative stress, promotion of hair growth, prevention of white hair and inhibition of scalp aging.

The invention discloses a ferroptosis inhibitor for improving liver toxicity of a GPR40 agonist TAK-875. The ferroptosis inhibitor comprises an iron complexing agent, an antioxidant, a lipoxygenase (LOX) inhibitor, an ACSL4 inhibitor, nitrogen oxide and selenium supplement, the iron complexing agent comprises deferoxamine, deferiprone, Deferasirox, curcumin and hepcidin, so that unstable iron in cells can be reduced, and a Fenton reaction can be inhibited; the antioxidant is prepared from Ferrostain-1, Liproxstain-1, Trolox and XJB-5-131, and the antioxidant is prepared from the following raw materials: sodium alginate, sodium alginate and sodium alginate; the lipoxygenase (LOX) inhibitor comprises Zileuton, AA861, PD146176 and baicalin, the ACSL4 inhibitor comprises Troglitazole, Rosiglitazole and Pioglitazole, the nitrogen oxides comprise TEMPO and PHOXNO, the Fenton reaction can be blocked, and the generation of hydroxyl free radicals can be inhibited; the selenium supplement comprises selenium, methyl selenocysteine and selenocystamine, the abundance of GPX4 is supplemented, and the lipid peroxide removing capacity is enhanced. Compared with the prior art, the invention has the advantage that the iron inhibitor is effectively proved to treat hepatotoxicity.

The invention belongs to the technical field of microbial fermentation, and discloses a solid-state fermentation postbiotic for adjusting the 5-hydroxytryptamine level and a preparation method and application of the solid-state fermentation postbiotic, and the solid-state fermentation postbiotic comprises fermented fermentation lactobacillus mucus IOB802 inactivated thallus components, metabolites and fermentation substrate active components. According to the invention, after solid state fermentation, by adjusting the content of neurotransmitters such as 5-hydroxytryptamine and then adjusting the relative expression level of neuronal cell apoptosis related genes Bcl-2 and Caspase 3 mRNA, nerve injury caused by sleep disorder is further improved. Meanwhile, after solid state fermentation, the prebiotics can improve oxidative stress injury caused by sleep disorder by reducing the content of lipid peroxide malonaldehyde and increasing the content of antioxidant enzyme.

The invention relates to application of a compound of colla corii asini and honey in preparation of an antioxidant product, and belongs to the technical field of health-care food. The donkey-hide gelatin disclosed by the invention is derived from Dongu donkey-hide gelatin Co., Ltd. The compound of colla corii asini and honey has the effects of reducing oxidative stress, enhancing free radical scavenging capacity and resisting oxidation. After the antioxidant compound is taken for a long time, the elimination capability of mice on lipid peroxide can be improved, the oxidative stress degree of organisms can be slowed down, the reserve of glutathione can be increased, the oxidative damage degree of amino acid can be reduced, and finally the antioxidant effect can be achieved. The invention provides a new component for research and development of health-care food with antioxidant activity, and has important application value.

The application discloses a selenium-based metal polyphenol-based nanoparticle and a preparation method and application thereof, and belongs to the technical field of biological materials. The selenium-based metal polyphenol-based nanoparticle is composed of a selenium-based catalytic center, metal ions and non-enzyme molecular ligands, and a stable nano structure is constructed through coordination of the metal ions and polyphenols. The application also discloses a preparation method of the nano enzyme. The nano enzyme can efficiently remove lipid peroxides and lipid hydroperoxides under the participation of glutathione, and has very low non-specific catalytic activity to the POD pathway. The nanoparticle has good biocompatibility, can effectively reduce lipid peroxidation damage induced by oxidative stress, and can maintain the stability of the structure and function of the cell membrane, and can be used for prevention and treatment of oxidative stress-related diseases, and is especially suitable for diseases with lipid peroxidation and ferroptosis as the main pathological mechanism.

The present invention relates to the use of fermented lactobacillus grx08 in the preparation of food, functional food and medicine with the effect of alleviating alcoholic liver damage and related symptoms thereof, and the preservation number of the fermented lactobacillus grx08 is CGMCC No: 7695. The fermented lactobacillus grx08 has the effect of reducing alcohol dehydrogenase and alleviating and restoring the balance of ethanol metabolism. The fermented lactobacillus grx08 has the effect of reducing alanine aminotransferase, reducing liver lipid accumulation, reducing liver lipid peroxidation products, and alleviating liver damage. Animal experiments have shown that fermented lactobacillus grx08 (CGMCC No: 7695) can restore the metabolic balance of rat alcohol dehydrogenase, reduce the level of alanine aminotransferase, reduce lipid accumulation and lipid peroxides in the liver, and alleviate liver damage. In addition, fermented lactobacillus grx08 can also alleviate kidney damage, enhance the tight connectivity of rat intestines, reduce inflammatory factors in the body, and alleviate the increase in blood sugar caused by acute alcohol intervention.

The invention discloses a metal nano-material and a preparation method and application thereof in tumor resistance, and relates to the field of metal nano-materials, linoleic acid modified polydopamine coated nano-iron metal nano-materials are constructed by taking nano-iron as a core, coating a polydopamine layer and modifying linoleic acid, the preparation method is simple and convenient to operate, the condition is mild, the cost is low, and the metal nano-material is suitable for industrial production. The repeatability is good. And in the application of tumor treatment, excellent performance is shown. Due to the photo-thermal performance, local high temperature can be generated under irradiation of near-infrared light, tumor cells are directly killed, and drug release is promoted; the nano iron powder participates in an iron death process, and cooperates with linoleic acid to promote lipid peroxide accumulation and activate an iron or copper death pathway; linoleic acid can also improve the anti-tumor function of CD8 + T cells through metabolic reprogramming, and efficient cooperation of photothermal therapy, ferroptosis and immunotherapy is achieved. The material effectively overcomes the limitation of traditional single treatment, remarkably improves the treatment effect, reduces the side effects of the whole body, and provides an innovative solution for multi-mode combined treatment of tumors.

The invention belongs to the technical field of biological medicines, and particularly relates to a bisphenol compound for inducing ferroptosis and application thereof. According to the invention, HCC cells are treated by TMBPS, and lipid peroxide, Fe < 2 + >, malondialdehyde, reduced glutathione or oxidized glutathione, and mitochondrial morphology and potential in the HCC cells are detected. Target spots of TMBPS are predicted through a molecular docking method, and verification is carried out through quantitative real-time polymerase chain reaction, western blot and cell heat transfer experiments. The result of the embodiment shows that the TMBPS can induce ferroptosis of the HCC cells by increasing the levels of lipid peroxide, Fe < 2 + > and malondialdehyde in the cells and reducing the ratio of reduced glutathione or oxidized glutathione and the mitochondrial potential at the same time, and furthermore, the cell death triggered by the TMBPS in the HCC cells is related to ferroptosis and is mediated by inhibiting SLC7A11 expression.

The application discloses a 4-(benzo[d]thiazol-2-yl)benzene-1,2-ethylenediamine compound and a preparation method and application thereof. The structural formula of the compound is: the compound has strong ROS scavenging capacity, inhibits lipid peroxidation, can inhibit ferroptosis caused by an iron death inducer, can reduce brain ischemia and nerve damage caused by brain ischemia, and can relieve symptoms of Parkinson's syndrome and other neurological diseases. Therefore, the ferroptosis inhibitor based on the ferrostain-1 / lirilad structure provided by the application can treat diseases related to ferroptosis through multiple actions and has the potential to be developed into a drug for treating diseases related to ferroptosis. Moreover, the ferroptosis inhibitor can be used as an antioxidant fluorescent probe for high-sensitivity detection of a ferroptosis marker, lipid peroxide (PCOOH / PEOOH), can effectively reverse the ferroptosis process of cells, and has a self-indication capacity. The ferroptosis inhibitor is a solid powder, is convenient to store and use, has a simple synthesis method, high yield, low cost, and good popularization prospect.

The invention discloses an active oxygen response type polymer prodrug micelle, and further discloses a polymer prodrug micelle loaded with oridonin or dihydroartemisinin and a polymer prodrug micelle loaded with the oridonin and the dihydroartemisinin at the same time. The invention further provides a preparation method of the polymer prodrug micelle. The ORI and DHA co-loaded active oxygen responsive polymer prodrug micelle provided by the invention can significantly improve the water solubility and biocompatibility of ORI and DHA, can effectively eliminate reduced glutathione in gastric cancer cells AGS cells and amplify active oxygen, and finally causes the generation of a large amount of lipid peroxides, thereby killing tumor cells and inducing cell ferroptosis, and has a good application prospect. And finally, tumor proliferation is inhibited.

The invention discloses application of NAC in preparation of a medicine for treating temporomandibular joint disorder, and particularly discloses application of the medicine in effectively improving TMD joint tissue oxidation resistance, inhibiting inflammation level, promoting extracellular matrix secretion and inhibiting iron (ferrous) ions and lipid peroxides so as to improve cartilage injury, relieve pain in a condylar process region and improve osteoarthritis. As a clinical common medicine, NAC is low in cost, high in availability, excellent in cell and tissue safety and high in practicability. The medicine can be safely applied to TMD treatment by means of condyle local injection or condyle region skin application (microneedle) and the like, has important significance in clinical medication of TMD, and has good medication value and application prospect.

The invention discloses a preparation method of astaxanthin immobilized probiotic vesicles capable of resisting ionizing radiation liver injury, and belongs to the field of biological medicines. Preparing probiotic vesicles by taking lactobacillus rhamnosus as a raw material; the preparation method comprises the following steps: dissolving astaxanthin in absolute ethyl alcohol, dispersing vesicles in a phosphate buffer solution, mixing the two vesicles in a microreactor, and carrying out ultrasonic treatment to obtain astaxanthin-loaded probiotic vesicles; the immobilized probiotic vesicles loaded with the astaxanthin are obtained by incubating the immobilized probiotic vesicles with glutamine transaminase, so that the embedding rate and the loading rate of the astaxanthin are improved, and the immobilized probiotic vesicles have good biocompatibility and biological safety; the residence time of fat-soluble compounds in intestinal tracts is prolonged, and targeted enrichment of the liver is increased; x-ray induced active oxygen accumulation, mitochondrial dysfunction and DNA damage in cells are relieved, the antioxidant enzyme level is improved, and the lipid peroxide content is reduced; the liver injury caused by ionizing radiation is remarkably relieved by reducing oxidative stress and DNA injury of the liver and delaying cell apoptosis.

The present invention provides the following as individual embodiments: a method for inhibiting dysfunction caused by the accumulation of lipid peroxides in a living body or a biomaterial; a composition for inhibiting dysfunction caused by the accumulation of lipid peroxides in a living body or a biomaterial; and a low molecular compound capable of inhibiting the accumulation of lipid peroxides. The method for inhibiting dysfunction of a living body or a biomaterial includes inhibiting the accumulation of lipid peroxides in a living body or a biomaterial. Also provided are: a composition for dysfunction of a living body or a biomaterial, the composition containing a substance that inhibits the accumulation of lipid peroxides as an active ingredient; and a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

The present invention discloses the use of Mps1-IN-1 as a ferroptosis inhibitor and in the preparation of drugs for preventing and treating ferroptosis-related diseases, and belongs to the field of biomedicine technology. Specifically, any of the following applications of Mps1-IN-1 is proposed: 1. Application as a ferroptosis inhibitor; 2. Application in the preparation of drugs for preventing and / or treating ferroptosis-related diseases; 3. Application in constructing ferroptosis tumor cell models, etc. Beneficial effect: The inhibitor exhibits significant protective ability against cell fate under a variety of ferroptosis-inducing mechanisms. Its unique mechanism of action is not limited to simply inhibiting the ferroptosis process, but also lies in its ability to efficiently scavenge harmful oxygen free radicals and effectively curb the generation of lipid peroxides. This discovery has opened up a new way for the prevention and treatment of ferroptosis-related diseases. Its research and development and application not only have far-reaching scientific significance, but will also have a positive and far-reaching impact on human health.

The invention discloses an anti-aging beautifying oral liquid containing low-polymerization-degree chitosan oligosaccharide and a preparation method thereof, and belongs to the technical field of marine organisms. Chitosan oligosaccharide mainly comprising chitobiose and chitotriose is prepared by utilizing the synergistic fermentation effect of microorganisms, and the chitosan oligosaccharide is compounded with collagen, sodium hyaluronate, vitamin C and the like to prepare the oral liquid. The low-polymerization-degree chitosan oligosaccharide is an excellent in-vivo antioxidant, can remove excessive free radicals, inhibit lipid peroxidation and slow down damage of metabolites such as peroxided lipid to the body, and then the anti-aging effect is achieved; the anti-aging and beautifying oral liquid prepared by matching natural moisturizing and beautifying components such as collagen and sodium hyaluronate is good in taste and easy to absorb, and animal experiment results show that the anti-aging and beautifying oral liquid can have beautifying and anti-aging effects after being frequently taken.

The invention discloses a pericarpium citri reticulatae microcapsule, a preparation method thereof and application of the pericarpium citri reticulatae microcapsule in resisting acute lung injury. The core material of the pericarpium citri reticulatae microcapsule is the pericarpium citri reticulatae extract, the wall material of the pericarpium citri reticulatae microcapsule is hydroxypropyl-beta-cyclodextrin, and the pericarpium citri reticulatae microcapsule can improve LPS-induced cell injury and peroxidation injury, reduce formation of lipid peroxides, reduce ROS level in cells, reduce MDA content and increase SOD and CAT activity, has good acute lung injury resistance activity, and can be used for preparing a medicine for treating acute lung injury. The effect of preparing the medicine for resisting acute lung injury is better than that of the pericarpium citri reticulatae extract prepared by the traditional extraction method and the micro gum of the pericarpium citri reticulatae extract. Meanwhile, the tangerine peel microcapsule provided by the invention is simple and quick in preparation method, can improve the stability of the tangerine peel extract, has the advantages of sustained release, good water solubility, small irritation, high safety and the like, can relieve lung inflammation and promote lung function recovery, has very good acute lung injury resisting activity, and can be used for preparing the oral preparation. The traditional Chinese medicine composition is used for preparing more natural medicines for resisting acute lung injury.

The present application relates to the use of [10]-shogaol in the preparation of a medicament for preventing and / or treating tumors sensitive to ferroptosis. Specifically, the present application provides a method for screening ferroptosis inducers, comprising the following steps: taking cells sensitive to ferroptosis, applying a candidate compound to a test group, applying [10]-shogaol to a positive control group, applying [6]-shogaol to a non-ferroptosis inducer group, and not applying any compound to a blank control group; detecting the lipid peroxidation level in the cells of each group; comparing the lipid peroxidation levels of the test group and the other groups to detect whether the candidate compound is a ferroptosis inducer. The [10]-shogaol can effectively induce ferroptosis in various malignant tumor cells such as breast cancer, colorectal cancer, melanoma, etc., and the mechanism of action depends on the accumulation of lipid peroxidation, and this effect can be specifically blocked by ferroptosis inhibitors.

An object of the present invention is to provide a low molecular weight compound having an anti-ferroptosis activity and an ability to scavenge lipid peroxy radicals which is relatively highly safe when ingested, can be orally ingested, and can be manufactured at a relatively low cost. The present invention provides a ferroptosis inhibitor, an agent for preventing or treating a disease associated with ferroptosis, a lipid peroxy radical scavenger, or an agent for preventing or treating a disease caused by lipid peroxide accumulation and / or lipid peroxy radicals, comprising one or more compounds selected from the group consisting of compounds of the following formula (I) to formula (III):(wherein R represents H; a substituted or unsubstituted, linear or branched C1-20 alkyl group; a substituted or unsubstituted, linear or branched C2-20 alkenyl group; or —(CH2CH═CH(CH3)CH2)nH [wherein n represents an integer of 1 to 12]) and physiologically acceptable salts thereof.

The invention discloses application of Mps1-IN-1 as a ferroptosis inhibitor and in preparation of drugs for preventing and treating ferroptosis-related diseases, and belongs to the technical field of biological medicines. The invention specifically provides any one of the following applications of Mps1-IN-1: 1, application as a ferroptosis inhibitor; 2, application in preparation of drugs for prevention and / or treatment of ferroptosis related diseases; 3, application in construction of a ferroptosis tumor cell model, and the like. The inhibitor has the beneficial effects that the inhibitor shows a remarkable protection capability on cell fate under various ferroptosis induction mechanisms, the unique action mechanism of the inhibitor is not limited to simple inhibition of a ferroptosis process, and the inhibitor can efficiently remove harmful oxygen free radicals and effectively inhibit the generation of lipid peroxides. The discovery opens up a new way for prevention and treatment of ferroptosis-related diseases, and the research and development and application have profound scientific significance and bring positive and profound influence on human health undertaking.

This invention discloses a novel application of undecanoic acid in inducing ferroptosis in laryngeal cancer cells and in the preparation of anti-laryngeal cancer drugs. For the first time, it was discovered that the known compound undecanoic acid can specifically target the mitochondria of laryngeal cancer cells, inducing mitochondrial structural damage and dysfunction. This, in turn, activates the ferroptosis pathway through multiple mechanisms, including increasing intracellular ferrous ion accumulation, increasing lipid peroxide levels, downregulating GPX4 / SLC7A11 expression, and upregulating ACSL4 expression, thereby effectively inhibiting the proliferation of laryngeal cancer cells. Based on this mechanism, this invention provides a pharmaceutical composition with undecanoic acid as the active ingredient, and its combined application with platinum-based drugs (such as cisplatin). This combined treatment exhibits a significant synergistic effect, particularly overcoming the platinum resistance of laryngeal cancer cells. This invention provides a novel drug selection and combination therapy strategy for the treatment and prevention of laryngeal cancer and precancerous lesions.

This invention belongs to the field of biomedical technology and provides an application of a ferroptosis inhibitor in the treatment of hepatitis. This invention reveals that a GRIM-19 gene defect specifically induces ferroptosis in hepatocytes, rather than other cell death mechanisms such as apoptosis, necrosis, or autophagy. This invention provides a ferroptosis inhibitor with Ferrostatin-1 as the active ingredient, solving the technical problem of insufficient intervention against the ferroptosis mechanism in existing hepatitis treatments. This inhibitor can significantly increase the expression level of GPX4 in liver tissue, effectively clear lipid peroxides, a core toxic product in the ferroptosis process, and block the ferroptosis process; in addition, it can significantly inhibit the activation of the NLRP3 inflammasome and reduce the expression of downstream inflammatory factors, thereby alleviating inflammatory cell infiltration and fibrotic lesions in the liver. This invention is applicable to the treatment of GRIM-19 deficiency-related chronic hepatitis, providing a new strategy for targeted therapy of liver diseases.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a platinum (IV) prodrug with ferroptosis and apoptosis induction effects as well as a preparation method and application of the platinum (IV) prodrug. According to the invention, a novel platinum (IV) compound with a ferroptosis induction effect is developed based on platinum (IV) prodrugs of salazosulfapyridine, cis-platinum and carboplatin; the platinum (IV) prodrug disclosed by the invention shows excellent anti-proliferative activity to cisplatin-sensitive and drug-resistant triple negative breast cancer cells, and compared with cisplatin, the platinum (IV) prodrug has lower activity to a normal mammary gland cell line (MCF-10A). Accumulation of reactive oxygen species (ROS) in cells can be improved by inducing DNA damage, and a mitochondrial dependent approach is activated to induce apoptosis. Meanwhile, accumulation of lipid peroxide can be remarkably promoted, xCT and GPX4 levels are reduced, and mitochondrial morphological change is induced to stimulate ferroptosis; in vivo, the cis-platinum (IV) prodrug shows strong anti-tumor activity in an MDA-MB-231 / CDDP xenograft model, and the cis-platinum (IV) prodrug has strong anti-tumor activity; the platinum (IV) prodrug has a potential application prospect in targeted therapy of triple negative breast cancer.